Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 06 12:05PM ET
15.06
Dollar change
+0.10
Percentage change
0.68
%
IndexRUT P/E- EPS (ttm)-0.38 Insider Own5.71% Shs Outstand43.12M Perf Week4.23%
Market Cap660.15M Forward P/E90.37 EPS next Y0.17 Insider Trans0.00% Shs Float41.33M Perf Month10.67%
Income-16.54M PEG- EPS next Q0.01 Inst Own81.04% Short Float2.97% Perf Quarter40.76%
Sales173.48M P/S3.81 EPS this Y89.22% Inst Trans-9.19% Short Ratio2.70 Perf Half Y156.59%
Book/sh2.18 P/B6.90 EPS next Y1009.11% ROA-8.69% Short Interest1.23M Perf Year283.25%
Cash/sh0.62 P/C24.33 EPS next 5Y- ROE-17.15% 52W Range3.92 - 15.37 Perf YTD120.52%
Dividend Est.- P/FCF- EPS past 5Y3.44% ROI-10.15% 52W High-2.01% Beta1.08
Dividend TTM- Quick Ratio2.32 Sales past 5Y13.87% Gross Margin77.79% 52W Low284.23% ATR (14)0.68
Dividend Ex-DateJan 27, 2010 Current Ratio3.51 EPS Y/Y TTM30.61% Oper. Margin-7.04% RSI (14)65.04 Volatility5.76% 4.78%
Employees428 Debt/Eq0.72 Sales Y/Y TTM17.26% Profit Margin-9.53% Recom1.14 Target Price16.43
Option/ShortYes / Yes LT Debt/Eq0.70 EPS Q/Q71.69% Payout- Rel Volume0.52 Prev Close14.96
Sales Surprise10.48% EPS Surprise178.12% Sales Q/Q25.57% EarningsNov 07 BMO Avg Volume455.80K Price15.06
SMA208.18% SMA509.22% SMA20055.35% Trades Volume101,064 Change0.68%
Date Action Analyst Rating Change Price Target Change
Jul-01-24Initiated Raymond James Outperform $13
Nov-11-22Resumed Jefferies Buy $15
May-09-22Upgrade Canaccord Genuity Hold → Buy $10 → $15
Mar-11-22Resumed Cantor Fitzgerald Overweight $21
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Oct-24-24 07:00AM
Oct-14-24 07:21AM
Oct-09-24 05:30PM
Sep-12-24 01:30AM
Sep-06-24 07:00AM
09:15AM Loading…
Sep-04-24 09:15AM
Sep-03-24 07:00AM
Aug-30-24 12:00PM
Aug-23-24 09:55AM
Aug-19-24 09:15AM
Aug-13-24 04:18PM
Aug-09-24 12:56AM
Aug-08-24 08:20AM
07:19AM
07:05AM
07:00AM Loading…
07:00AM
Aug-01-24 10:01AM
Jul-23-24 07:00AM
Jul-12-24 08:37AM
Jul-01-24 07:00AM
Jun-25-24 12:52PM
Jun-24-24 07:00AM
Jun-12-24 04:56AM
May-28-24 04:30PM
May-17-24 12:29PM
May-16-24 02:56PM
07:00AM
May-14-24 07:00AM
May-06-24 10:31AM
May-03-24 03:02AM
11:57AM Loading…
May-02-24 11:57AM
08:15AM
07:14AM
07:00AM
Apr-29-24 04:50PM
Apr-16-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:20AM
Mar-05-24 09:27PM
11:53AM
07:38AM
07:31AM
07:00AM
Feb-28-24 08:50AM
Feb-26-24 09:15AM
Feb-13-24 04:30PM
Feb-12-24 08:50AM
Feb-06-24 09:40AM
Feb-02-24 04:15PM
Jan-26-24 08:50AM
Jan-18-24 05:00PM
Jan-04-24 04:45PM
04:40PM
04:35PM
Dec-26-23 04:15PM
Dec-06-23 07:00AM
Dec-01-23 05:00PM
Nov-20-23 07:00AM
Nov-08-23 09:41AM
Nov-07-23 11:01PM
08:04AM
07:15AM
07:00AM
Nov-02-23 10:00AM
Oct-31-23 10:01AM
Oct-18-23 07:00AM
Oct-16-23 10:23AM
Sep-28-23 08:21AM
Sep-05-23 07:00AM
Aug-31-23 07:00AM
Aug-21-23 07:00AM
Aug-10-23 03:03PM
12:05PM
Aug-08-23 10:59AM
05:57AM
Aug-07-23 05:25PM
04:18PM
04:01PM
Aug-03-23 05:55PM
Jul-27-23 07:00AM
Jul-26-23 07:00AM
Jun-10-23 10:42AM
Jun-09-23 09:55AM
May-24-23 07:00AM
May-12-23 07:00AM
May-09-23 08:35AM
07:34AM
07:00AM
Apr-18-23 04:05PM
07:25AM
Mar-17-23 04:31AM
Mar-16-23 06:30AM
Mar-14-23 11:23PM
07:00AM
Mar-06-23 07:00AM
Mar-02-23 04:00PM
Mar-01-23 09:21AM
Feb-13-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 07:00AM
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zaderej Karen L.SENIOR ADVISORSep 05 '24Proposed Sale13.00150,0001,950,000Sep 05 04:33 PM
JOHNSON JOHNDirectorSep 01 '24Option Exercise0.0011,904029,016Sep 04 09:13 PM
NEELS GUIDO JDirectorSep 01 '24Option Exercise0.0011,904090,816Sep 04 09:11 PM
Levine Alan MDirectorSep 01 '24Option Exercise0.0011,904040,816Sep 04 08:58 PM
Burke William P. Mr.DirectorSep 01 '24Option Exercise0.0011,904028,557Sep 04 08:52 PM
THOMAS PAULDirectorSep 01 '24Option Exercise0.0011,904032,052Sep 04 08:33 PM
TYNDALL JOSEPH A.DirectorSep 01 '24Option Exercise0.0011,904022,557Sep 04 07:52 PM
Wendell Amy McBrideDirectorSep 01 '24Option Exercise0.0011,9040102,899Sep 04 05:18 PM
Donovan Michael PatrickOfficerAug 21 '24Proposed Sale12.4228,003347,810Aug 21 04:31 PM
GREG FREITAGDirectorAug 13 '24Proposed Sale11.1715,000167,520Aug 13 05:00 PM
Zaderej Karen L.SENIOR ADVISORAug 12 '24Proposed Sale10.00200,0002,000,000Aug 12 10:59 AM
Freitag Gregory GeneDirectorJun 04 '24Option Exercise0.0011,9040283,498Jun 06 04:49 PM
Zaderej Karen L.CEOMar 16 '24Option Exercise0.00110,32201,157,593Mar 25 09:43 PM
Zaderej Karen L.CEOMar 21 '24Sale7.6839,280301,6701,124,565Mar 25 09:43 PM
DeVinney Erick WayneChief Innovation OfficerMar 16 '24Option Exercise0.0018,6750180,615Mar 25 09:40 PM
DeVinney Erick WayneChief Innovation OfficerMar 21 '24Sale7.684,57835,159165,661Mar 25 09:40 PM
Scopelianos AngeloChief R&D OfficerMar 21 '24Option Exercise0.002,500058,604Mar 25 09:37 PM
Scopelianos AngeloChief R&D OfficerMar 16 '24Option Exercise0.0025,406058,250Mar 25 09:37 PM
Scopelianos AngeloChief R&D OfficerMar 21 '24Sale7.686,88152,84652,999Mar 25 09:37 PM
Donovan Michael PatrickVP OperationsMar 16 '24Option Exercise0.0024,575058,846Mar 25 09:22 PM
Donovan Michael PatrickVP OperationsMar 21 '24Sale7.686,03346,33337,992Mar 25 09:22 PM
Donovan Michael PatrickVP OperationsMar 07 '24Sale8.8136,310319,89135,708Mar 08 05:33 PM
Freitag Gregory GeneDirectorMar 07 '24Sale9.0025,000225,000271,594Mar 08 05:31 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 11 '23Sale7.5012,50093,80963,603Dec 13 04:07 PM